- Conditions
- Migraine
- Interventions
- Ubrogepant, Placebo-Matching Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 1,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 125
- States / cities
- Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 40
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Migraine
- Interventions
- Eptinezumab
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 20
- States / cities
- New Haven, Connecticut • Stamford, Connecticut • Gulf Breeze, Florida + 17 more
- Conditions
- Migraine in Children
- Interventions
- Valproic Acid (VPA), Dihydroergotamine (DHE)
- Drug
- Lead sponsor
- Kimberly S Jones
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 38
- States / cities
- San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
- Interventions
- Not listed
- Lead sponsor
- Brain Inflammation Collaborative
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Delafield, Wisconsin
- Conditions
- Migraine, Abdominal Pain
- Interventions
- thermal biofeedback, relaxation training, cognitive coping skills, parent education
- Behavioral
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Irritable Bowel Syndrome (IBS), Functional Abdominal Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS), Myofacial Pain, Chronic Daily Headaches, Migraine Headaches, Chronic Pain
- Interventions
- Mentorship
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Childhood Depression, Childhood Anxiety, Pediatric Pain, Migraines, ADHD, Pediatric Stomach Pain, Musculoskeletal Pain
- Interventions
- Integrative Coping Group
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Acute Treatment of Migraine
- Interventions
- Zavegepant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Washington D.C., District of Columbia • Hinesville, Georgia + 8 more
- Conditions
- Migraine
- Interventions
- Nerivio
- Device
- Lead sponsor
- Theranica
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 293 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Migraine Disorders, Headache Disorders
- Interventions
- SPN-538, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Migraine Disorders
- Interventions
- Qudexy XR, Placebo
- Drug
- Lead sponsor
- Upsher-Smith Laboratories
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 12 more
- Conditions
- Migraine
- Interventions
- Lasmiditan
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Newport Beach, California • Stamford, Connecticut + 5 more
- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 38
- States / cities
- San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
- Conditions
- Pediatric Migraine
- Interventions
- Rimegepant/BHV3000, Matching placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 2,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 106 more
- Conditions
- Insomnia, Migraine Disorders, Headache Disorders
- Interventions
- Internet-delivered CBT for Insomnia, Internet-delivered CBT for Pain Management, Internet-delivered Sleep Education
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 56
- States / cities
- Fort Smith, Arkansas • Hawthorne, California • La Mesa, California + 42 more
- Conditions
- Migraine in Children, Migraine
- Interventions
- Eptinezumab
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Stamford, Connecticut • Gulf Breeze, Florida • West Palm Beach, Florida + 6 more
- Conditions
- Migraine in Children, Sphenopalatine Neuralgia, Migraine in Adolescence
- Interventions
- Lidocaine topical, Prochlorperazine Injection
- Drug
- Lead sponsor
- Newark Beth Israel Medical Center
- Other
- Eligibility
- 10 Years to 20 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Migraine Disorders
- Interventions
- Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline)
- Biological · Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more
- Conditions
- Episodic Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
- Conditions
- Migraine Headaches
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Migraine
- Interventions
- AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more